Rani Therapeutics (RANI)
(Real Time Quote from BATS)
$0.54 USD
+0.01 (1.31%)
Updated Aug 8, 2025 11:42 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RANI 0.54 +0.01(1.31%)
Will RANI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RANI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for RANI
Rani Therapeutics GAAP EPS of -$0.18 beats by $0.02
Rani Therapeutics Holdings Inc Reports Q2 2025 EPS of -$0.18, Beating Estimates
12 Health Care Stocks Moving In Tuesday's Intraday Session
Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
Rani Therapeutics (RANI) Secures $3M Direct Offering Deal